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Abstract Coronary artery bypass grafting (CABG) has
been considered the standard therapy for unprotected
(nonrevascularized) left main coronary disease (ULM).
However, increasing experience with ULM percutaneous
coronary intervention (PCI) has resulted in high procedural
success and favorable early and late clinical outcomes. In
particular, reduction in clinical restenosis with drug-eluting
stents, evolution of procedural technique, and demonstra-
tion of favorable outcomes from comparative trials with
CABG have promoted consideration of PCI as an alterna-
tive revascularization strategy in selected patients with
ULM disease. This review summarizes the results from
comparative studies examining PCI versus CABG for ULM
disease, discusses changing indications for ULM PCI and
identifies outstanding issues that must be considered before
further advancing treatment recommendations.
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Angiographic Results: Drug-Eluting
Stents for Unprotected Coronary
Left Main Lesions
MAIN-COMPARE Revascularization for Unprotected
Left Main Coronary Artery Stenosis:
Comparison of Percutaneous
Coronary Angioplasty V ersus Surgical
Revascularization from Multicenter
Registry
SYNTAX Synergy Between Percutaneous
Coronary Intervention with TAXUS
and Cardiac Surgery
Introduction
In a lesion subset once routinely excluded from interven-
tional cardiology trials, recent successes principally in
nonrandomized comparative trials of drug-eluting stents
(DES) and coronary artery bypass grafting (CABG) in
unprotected left main coronary disease (ULM) revascu-
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DOI 10.1007/s11886-011-0196-zlarization have supported the rationale to revisit estab-
lished conventions for treatment and broaden therapeutic
options. Although varied in trial design, methods, and
study population size, these trials suggest clinical
equipoise for percutaneous coronary intervention (PCI)
and CABG with consistently similar rates of combined
safety outcomes of death, myocardial infarction, and
stroke [1￿￿]. In selected instances, new insights from
recent studies have identified patient characteristics for
which PCI may represent an acceptable alternative or
possibly even preferred strategy. Accordingly, societal
guidelines for ULM PCI have recently been revised. For
example, the 2009 United States focused guidelines for
PCI support consideration of ULM stenting in patients
with anatomic conditions that are associated with a low
risk of PCI-related procedural complications and clinical
conditions that predict an increased risk of adverse
surgical outcomes (class IIb) [2￿￿]. Similarly, the 2010
European societal guidelines have advanced the indication
for ULM PCI to either a IIa or IIb recommendation
depending upon the extent and complexity of both left
main and non-left main coronary disease [3￿￿]. Consider-
ing the increasing focus on ULM PCI in clinical practice,
the purpose of this document is to review the strengths and
deficiencies of existing evidence that may support (or
dismiss) ULM PCI, provide guidance regarding clinical
decision making and address outstanding concerns that
must be satisfied before further redefining standards for
ULM revascularization.
Contemporary Trials in ULM Percutaneous
Revascularization
Until recently, only modest evidence was available to
support ULM PCI in patients ineligible for CABG with
even less evidence to endorse PCI as a routine therapy for a
broader patient population. Early discouraging reports with
balloon angioplasty or bare metal stents (BMS) were
confounded by poor patient selection and nascent proce-
dural technique, contributing to at best inconsistent
intermediate-term clinical outcomes and at worst unaccept-
ably high rates of restenosis-related complications manifest
as repeat revascularization, myocardial infarction, or even
sudden cardiac death. However, encouraged by small,
randomized experience and comparisons from observational
trials or subgroup analysis, more contemporary studies
evaluating DES for ULM disease and with longer-term
follow-up have demonstrated remarkably consistent and
favorable “hard” end points of death, myocardial infarction,
and repeat revascularization [1￿￿, 4, 5].
Outcomes of DES and BMS in ULM lesions parallel
those in less complex lesion subsets, with significant
reductions in restenosis and repeat revascularization and,
at least similar safety outcomes of death, myocardial
infarction, and stent thrombosis. In a recent meta-analysis
of trials comparing BMS and DES in ULM revasculariza-
tion (N=5,081), treatment with DES was associated with
significant reduction in the 3-year rates of death (odds ratio
[OR], 0.70; 95% CI, 0.53–0.92; P=0.01), myocardial
infarction (OR, 0.49; 95% CI, 0.26–0.92; P=0.03), and
repeat revascularization (OR, 0.46; 95% CI, 0.30–0.69; P<
0.01) [6]. Although treatment with DES is preferred,
outcomes with conventional BMS are important because
their use (or CABG) may be favored over DES if there is
increased bleeding risk, impending noncardiac surgery that
requires discontinuation of dual antiplatelet therapy, and
treatment of large diameter vessels (≥5 mm) that exceed
DES diameter availability. Although outcomes may have
been influenced by selection and treatment bias, recent
nonrandomized comparison of BMS and CABG for ULM
revascularization in the ASAN-MAIN registry reported lower
unadjusted long-term rates of death and the composite of
death, Q-wave myocardial infarction, and stroke with BMS
comparedwithCABG (CABG;15.9%vs24.1%;P=0.02and
25.2% vs 32.1%; P=0.04, respectively); however, rate of
target vessel revascularization was significantly higher in the
BMS cohort (36.7% vs 4.9%; P<0.001) [7].
Recent trials and pooled analysis have provided impor-
tant perspective to the safety and efficacy of ULM
revascularization with DES compared with CABG. The
nonrandomized MAIN COMPARE trial involving 2,240
patients with ULM disease compared outcomes with PCI
(DES 71%/BMS 29%) or CABG [8￿]. Notably there was
less diabetes or multivessel coronary disease in the PCI
cohort. At 5-year follow-up, according to propensity score
adjustment including 542 matched patient pairs, ULM PCI
was associated with similar mortality (hazard ratio [HR],
1.02; 95% CI, 0.74–1.39) and the composite outcome of
death, Q-wave myocardial infarction, and stroke (HR, 1.10;
95% CI, 0.74–1.38) [9]. However, repeat revascularization
was significantly more common with PCI compared with
CABG (HR, 4.55; 95% CI, 2.88–7.20). Analysis following
risk adjustment but limited to patients treated with CABG or
DES (396 patient pairs) resulted in similar outcomes. These
data represent an important contribution to our understanding
of ULM PCI but must be cautiously interpreted given that
propensity adjustment in nonrandomized trials may not fully
correct for differences in patient populations.
In the randomized SYNTAX trial comparing CABG with
PCI for left main/multivessel disease, patient treatment
assignment was stratified according to presence of signif-
icant ULM disease. Of the ULM cohort (N=705), there
were approximately 60% with bifurcation disease and 13%
with isolated left main disease [10￿]. In the ULM subgroup,
despite significantly higher repeat revascularization for the
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P=0.004), and lower incidence of stroke in the PCI group
(1.2% PCI vs 4.0% CABG; P=0.02), outcomes of death
(7.3% PCI vs 8.4% CABG; P=0.64), myocardial infarction
(6.9% PCI vs 4.1% CABG; P=0.14), and the composite
end point of death/myocardial infarction/stroke (13.0% PCI
vs 14.3% CABG; P=0.60) remained similar between
treatment groups [11￿, 12]. These results are consistent
with those from a recent systematic overview of compar-
ative trials in ULM revascularization (N=3,773) reporting
similar safety outcomes between percutaneous and surgical
revascularization strategies but a higher rate of repeat
revascularization with PCI [13].
Regarding selection of DES, few comparative studies have
evaluated outcomes relative to DES type. In the randomized
ISAR-LEFT MAIN trial [14￿], PCI with either sirolimus-
eluting stents (SES) or paclitaxel-eluting stents (PES) was
associated with similar 2-year clinical events in both stent
groups (target lesion revascularization, 9.2% PES vs 10.7%
SES; P=0.47). Although to date no studies have compared
newer-generation DES to PES or SES in ULM PCI, ongoing
trials are comparing newer-generation DES to CABG. The
Nordic-Baltic-British Left Main Revascularization trial is
randomizing 1,200 patients with ULM and SYNTAX score
less than 22 to CABG or DES with end points of major
adverse cardiac events (MACE) at 2 years and death at
5 years. The EXCEL trial is a large, international trial in
which approximately 3,000 patients with ULM disease and a
SYNTAX score ≤32 will be randomized to revascularization
with everolimus-eluting stents or CABG.
Patient Selection and Predictive Models for Outcomes
Assessment Following ULM Revascularization
Although not all uncertainties must be satisfied to extend
ULM PCI as an alternative to surgery in broad patient
populations, presently available data do permit advancing
ULM PCI in more narrowly defined subgroups of patients.
However,translationofclinicaldataintoresultsmeaningfulto
an individual patient is challenging, and the presentation of
clinicaldatatopatientsmaybebiasedbypreferentialselection
of clinical studies and differential emphasis on end points (eg,
death vs repeat revascularization vs recovery and quality of
life). Specific to ULM revascularization, for which a surgical
standard of care has been historically established, and in
which both PCI and surgical alternatives may result in
divergentclinicaloutcomesfavoringeithertherapydepending
upon risk, a predictive model based on clinical and angio-
graphic characteristics seems essential to clinical decision
making and informing patients for consent.
The overall extent and complexity of both left main and
non-left main coronary disease are important for deciding
revascularization strategy. Although anatomic location of
disease within the left main segment has been identified as
an important predictor of clinical outcome following PCI
(detailed below), the extent, severity, and complexity of
non-left main disease may be an even greater determinant
of risk. Specifically, non-left main lesion complexity (eg,
chronic total occlusion, bifurcation disease, calcification)
may jeopardize the likelihood of procedural success and
limit completeness of revascularization, which was signif-
icantly less common among PCI than CABG patients in the
ULM subgroup of the SYNTAX trial [10￿]. Among patients
undergoing ULM PCI, the extent of coronary disease also
predicts likelihood of late-term major adverse events,
principally driven by increasing risk of repeat revascular-
ization [11￿, 12].
Risk scores are useful in determining the early and late
outcomes after PCI and CABG for ULM disease, and
discriminating between these two modalities for the individual
patient [15￿]. The EuroSCORE and Parsonnet score, which
are typically used to risk stratify CABG candidates, have been
applied both prospectively and retrospectively to patients
undergoing ULM PCI. An analysis from the MAIN-
COMPARE trial demonstrated that the EuroSCORE≥6w a s
an independent predictor of mortality in ULM patients who
undergo both percutaneous and surgical revascularization [16].
Similarly, increasing Parsonnet score was also identified as a
significant predictor of major adverse cardiac and cerebrovas-
cular events [16].
Predictive models, such as the SYNTAX score, may also
help discussions of risk and benefit during the consent
process for ULM revascularization [11￿, 17]. When the
SYNTAX score is in the highest tercile (≥ 33) indicating
extensive and/or complex coronary artery disease, surgical
revascularization may be favored over PCI. Alternatively,
patients with low (0–22) and intermediate (23–32) SYN-
TAX scores may have comparable composite safety and
efficacy outcomes with either treatment strategy [11￿]. At
3 years, in patients with ULM disease and SYNTAX
scores≥33, PCI patients had higher rates of repeat
revascularization than CABG (27.7% vs 9.2%; P<0.001)
and death (13.4% vs 7.6%; P=0.10) [12]. Conversely,
patients with ULM with low (0–22) and intermediate (23–
32) SYNTAX scores had similar rates of repeat revascular-
ization, myocardial infarction, death, or stroke or any
combination of these if treated by PCI or CABG. Although
these analyses from the left main cohort of the SYNTAX
trial are post hoc and statistically underpowered, they
currently represent the best level of evidence to guide
revascularization decisions, and have thus recently been
incorporated into societal guideline recommendations. As
an example, the 2010 European Society of Cardiology/
European Association for Cardio-Thoracic Surgery guide-
lines for myocardial revascularization have revised the
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without single vessel coronary disease to a class IIa
recommendation (weight of evidence favors its efficacy)
[3￿￿]. ULM PCI for ostial/shaft disease with two- or three-
vessel disease, or distal bifurcation disease of the left main
with two- or three-vessel disease and a SYNTAX score less
than 33 is provided a class IIb recommendation (usefulness
is less well established). Alternatively, a class III recom-
mendation for PCI is applied for ULM patients with a
SYNTAX score≥33 (evidence that treatment is not useful
and may be harmful).
For any risk model, prospective validation in an indepen-
dent patient population with ULM disease is essential.
Observational studies have externally validated the utility of
the SYNTAX score to predict mortality and major adverse
cardiac events in usual practice [18, 19]. In addition to the
SYNTAX score, the incorporation of clinical risk factors
besides angiographic characteristics may improve the pre-
dictive utility. The New Risk Stratification (NERS) model
includes clinical, procedural, and angiographic characteristics
[20]. For MACE, the sensitivity and specificity of an NERS
score ≥25 were 92.0% and 74.1%, respectively, representing
significantly higher predictive measures than SYNTAX
intermediate risk (20.5% and 25.4%) or SYNTAX higher
risk scores (70.5% and 35.2%; P<0.001 for all compar-
isons). Furthermore, an NERS score≥25 was the only
independent predictor of MACE and stent thrombosis.
Currently, no uniform consensus exists regarding the
most practical and accurate risk model for evaluating
patients with ULM disease. One additional challenge is
that patients considered for ULM PCI have been system-
atically excluded from many clinical trials, further restrict-
ing the generalizability of data to any individual patient.
Acknowledging the limitation that risk scores cannot
predict outcomes for individual patients with characteristics
not included in the model, construction of a risk model
must include appropriate and necessary preprocedural
clinical and angiographic characteristics while avoiding
overfitting the model [15￿].
Finally, excepting emergency indications, ad hoc PCI
should not be performed. Instead, the process for patient
selection and informed consent ideally should involve a
collaborative, multidisciplinary approach with a “Heart
Team” represented by both a cardiac surgeon and interven-
tional cardiologist, with both having the opportunity to
discuss with the patient the relative merits and risk of each
strategy [3￿￿]. Consultation with a non-interventional
cardiologist may also provide the patient more insight into
the treatment options. Recognizing the informed consent
process as an opportunity to optimize patient understanding
and objective decision making, the Heart Team represents a
balanced and integrated approach for multidisciplinary
decision making and consensus building.
Special Considerations for ULM Percutaneous
Revascularization
Left Main Lesion Complexity
Left main coronary lesion complexity has clear procedural
and clinical implications underscoring the need for proper
evaluation of both the distribution and severity of disease. To
this purpose, hemodynamic and intravascular ultrasound
(IVUS) assessment of left main coronary atherosclerotic
disease has associated the functional and/or anatomic rele-
vance of stenosis with the need for treatment and clinical
outcome [21, 22]. Specifically, an IVUS-derived minimal
luminal area of less than 6.0 mm
2 has been found to be a
useful cutoff value for clinically significant left main
coronary artery disease [23], and has been correlated with
hemodynamic significance by fractional flow reserve assess-
ment [22]. Recent IVUS studies have demonstrated that left
main atherosclerotic plaque burden is frequently more
extensive than predicted by angiography alone [24, 25]; in
particular, whereas atherosclerotic plaque is rarely present in
the carina (flow divider), extension of disease from the ostia
of the left anterior descending artery or left circumflex
arteries into the left main segment is very common.
Left main lesions not involving the distal bifurcation
(representing <40% of patients undergoing revascularization)
are associated with high procedural success rates and
favorable late-term outcomes of death, myocardial infarction,
and repeat revascularization. In a multicenter study of 147
patients undergoing ostial or shaft ULM PCI with DES, rates
of cardiac death rate and repeat target lesion revascularization
were 2.7% and 0.7%, respectively, during an average follow-
up periodof approximately 2.5 years [26]. In comparison, the
presence of distal bifurcation disease has repeatedly been
identified as one of the most significant predictors of repeat
revascularization and overall MACE after ULM PCI. A
meta-analysis of 17 trials involving ULM PCI identified the
presence of bifurcation disease as the most significant
predictor of repeat revascularization and overall MACE [27].
Procedural Technique
Percutaneous coronary intervention for ULM disease can be
technically challenging, requiring optimal strategies for treat-
mentof eithercomplex distalbifurcation disease orostial/shaft
stenosesthatjeopardizealargemyocardialterritory.Somewhat
surprisingly, however, procedural strategy and technique are
common practical considerations that are poorly addressed in
clinical trials describing left main revascularization. In part
related to this reason, optimal PCI strategies for ULM disease
are yet to be clearly defined. Moreover, strategies may vary
depending on different anatomic features of the entire
coronary anatomy and lesion morphology.
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more challenging and is associated with higher rates of
restenosis than isolated ostial or shaft disease, particularly
when two stents are used. When angiographic restenosis
does occur, it is most common at the ostium of the left
circumflex artery [28], a clinical observation that may be
dependent upon bifurcation angle and carina shift rather
than change in plaque geometry. In accord with published
results involving bifurcation stenting in non-left main
disease, uncontrolled studies of ULM bifurcation PCI favor
a single-stent provisional approach compared with inten-
tional two-stent techniques. Notably, one large study
reported comparatively higher rates of cardiovascular death
and target lesion revascularization with two-stent treatment
of bifurcation disease, including instances of unsuccessful
provisional approaches that required additional stent place-
ment [28]. In addition, several recent observational studies
have demonstrated nearly equivalent clinical outcomes with
single stent ULM bifurcation revascularization and left
main stenting for ostial or shaft disease [29–32]. Neverthe-
less, approximately 40% of ULM bifurcation treatment
involves a two-stent method [14￿, 28], yet the optimal two-
stent technique (eg, crush, culotte, V- or T-stenting) has not
been identified, and the procedure is instead determined
more by operator and institutional preference.
Intended as a solution to limitations of existing stent
designsincomplexanatomy,noveldedicatedbifurcationstent
designsareinearlyclinicaldevelopment[33], yet evidence to
support their procedural and clinical superiority over existing
standards has not been sufficiently demonstrated.
Aside from stent technique, additional procedural uncertain-
ties relate to use of IVUS and hemodynamic support. In many
circumstances, the application of IVUS may be invaluable to
assess optimally plaque distribution, bifurcation involvement,
and vessel calcification that are characteristics often poorly
defined by angiography alone. IVUS may also provide
important information regarding stent sizing, post deployment
stent expansion, and stent-wall apposition. Nevertheless, the
application of IVUS in ULM PCI trials has been inconsistent,
with some studies reporting improved survival with IVUS-
guided ULM PCI [34] and others describing favorable
outcomes despite negligible use of IVUS [14￿].
Similarly, patient-specific angiographic- and procedural-
related factors that predict the unplanned requirement for
adjunctive hemodynamic support during ULM PCI are
poorly characterized. In most instances, however, phar-
macologic or mechanical circulatory support is not
required; in the ISAR-LEFT MAIN trial, for example,
intra-aortic balloon pump counterpulsation was used in
less than 1% of the 607 patients undergoing ULM PCI
[14￿]. Although procedural-related complications [35]o r
hemodynamic compromise [36] may be reduced with
elective use of intra-aortic balloon pump counterpulsation
or alternative methods of hemodynamic support [37], a
reduction in adverse clinical outcomes (eg, myocardial
infarction, death) compared with their provisional use has
not been demonstrated.
Antiplatelet Therapy and Stent Thrombosis
DES placementin ULMdisease represents a dilemmabetween
the importance of avoiding restenosis and the risk of stent
thrombosis associated with delayed vessel healing. Given that
stent thrombosis is a devastating complication of PCI,
associated with a near uniform rate of myocardial infarction
and considerable mortality [38], its occurrence in the ULM
territory may have catastrophic clinical consequences. Fortu-
nately, ULM stent thrombosis is uncommon, and several
recent multicenter registries evaluating the occurrence of late
and very late stent thrombosis provide some reassuring and
remarkably consistent evidence to support DES treatment in
ULM disease. In the ISAR-LEFT MAIN trial, for example,
among 607 patients receiving DES for ULM disease, the
overall 2-year rate of Academic Research Consortium–
defined definite stent thrombosis was 0.5%, with no instances
beyond 30 days of the index procedure [14￿].
Thienopyridine discontinuation within 6 months of DES
implantation is a predictor of stent thrombosis [38]. In a
multicenter observational study, clopidogrel discontinuation
within the first 31 to 180 days following ULM DES
implantation was associated with a more than fourfold risk-
adjusted increase in cardiovascular mortality and myocar-
dial infarction compared with discontinuation beyond
180 days [39]. Alternatively, with dual antiplatelet therapy
extended beyond 1 year, combined data from two random-
ized trials with DES recently reported no significant
reduction in cardiovascular death, myocardial infarction,
or stent thrombosis [40] but only 3% of patients included in
this analysis underwent ULM PCI.
In ULM PCI clinical trials, the duration of antiplatelet
therapy has been variable, with no standardized recom-
mendations for aspirin and thienopyridine dosing or
duration. In addition, limited studies have focused on the
role of genomic and/or platelet reactivity testing to identify
patients with high on-treatment residual platelet activity
who may be at increased risk for subsequent ischemic
events [41]. Accordingly, the optimal duration of dual
antiplatelet therapy in patients stented for ULM disease has
not been established. Thus, expectations for patient com-
pliance and a reasonable assurance of no foreseeable
circumstances that might necessitate premature discontinu-
ation of antiplatelet therapy are important considerations.
CABG or even BMS should be considered if concerns are
present regarding bleeding risk, noncompliance, foreseeable
need for interruption, or contraindications to prolonged dual
antiplatelet therapy.
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Historically, routine surveillance angiography was common,
but considering the low rates of DES restenosis and stent
thrombosis following ULM revascularization, the clinical
utility of surveillance of angiography has been challenged.
In the LE MANS substudy (N=145) of the SYNTAX trial,
for example, angiographic restenosis (>50% stenosis) at
15-month follow-up was identified in only 2% (1/48) of
patients with ostial/shaft disease and 10% (10/97) of
patients with bifurcation disease [42]. In consideration of
these data and the recognition that scheduled nonsymptom-
driven angiography could result in unnecessary procedures,
the most recent guidelines no longer endorse its perfor-
mance [2￿￿]. However, noninvasive assessment of ischemia
is reasonable at 6 months and annually thereafter [1￿￿].
When clinical restenosis following ULM stenting is
identified, the most appropriate treatment is also uncertain. In
cases of intermediate significance, assessment of hemody-
namic significance with fractional flow reserve should be
performed.Iflesionsignificanceisconfirmed,IVUSmayalso
inform the mechanism of restenosis and should be performed
routinely for restenosis if repeat PCI is considered.
For patients with ULM restenosis, repeat revascularization
seems imperative, and PCI may be associated with favorable
outcomes. In a multicenter observational study of patients
with ULM restenosis treated with repeatPCI (N=70), the risk
of cardiovascular death was 1.7% over a mean follow-up
period of 35 months, with no occurrences of stent
thrombosis [43]. During the follow-up period, the risk of
MACE was lowest with CABG or repeat PCI compared with
medical therapy alone (MACE at 35 months, 14% CABG,
25% PCI, 50% medical therapy). Unlike after DES treatment
of de novo ULM disease, early follow-up angiography at 4
to 6 months should be considered if repeat PCI is performed
for ULM restenosis given higher risk of disease recurrence.
Conclusions
Over the past 5 years, an evidence base has emerged
supporting the consideration of ULM PCI as an alternative
revascularization strategy to CABG in selected patients. In
particular, trials reporting late-term safety outcomes of
cardiovascular death, myocardial infarction, and stroke
comparable to CABG have fostered renewed enthusiasm for
ULM PCI. In parallel, application of DES and advances in
technique and strategy have enhanced the rates of early
procedural and long-term clinical success of ULM PCI.
Ultimately,demonstrationofatleastclinicalequivalence in
a randomized trial comparing ULM PCI with surgery is
necessary before percutaneous revascularization can be
routinely accepted as an alternative to bypass surgery; to this
purpose, forthcoming trials designed with careful attention to
patient selection, timing of end-point ascertainment, and
relevance of safety and efficacy end points should inform
clinical decision making and treatment guidelines. However,
consistentwithmanylargecomparative trials,itismorelikely
that such studies may clarify which patients with ULM are
suitable for both or either therapies rather than demonstrate
clinical equivalence for a broadly defined patient population
with individual characteristics that pose variable risk.
Presently available data are substantive enough to support
ULM PCI in the absence of coexisting complex coronary
disease (eg, SYNTAX score≥33). Thus, an important focus
should be the responsibility of appropriate patient selection,
with consensus that represents full consultation ideally with
both an interventionalist and cardiac surgeon. Integration of
clinical and angiographic variables into risk models may
further refine assessment of patient risk for either revascular-
izationmethodandresponsiblyinformthe patientforconsent.
Aside from an emphasis on comparative clinical outcomes,
ongoing clinical trials intended to address the practical and
technique-related issues of ULM PCI and promote consensus
building between cardiology and surgical societies are
essentialtoadvance treatmentrecommendations andoptimize
the outcomes for patients with ULM coronary artery disease.
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